Table 1.
A summary of the ELPs, FAMEs, and control PAs used in this study.
Identifier |
N-terminal Modification |
Sequence |
||
---|---|---|---|---|
NMT Recognition sequences a) |
ELP | |||
B1-ELP | N/A | GAGASRGGSGGS | ||
ELPs | B2-ELP | N/A | GAGAGAYRGGSGGSGGS | |
B3-elp | N/A | GLSLSRGGSGGS | (GVGVP)40GY | |
M-B1-ELP | Myristoyl | GAGASRGGSGGS | ||
FAMEs | M-B2-ELP | Myristoyl | GAGAGAYRGGSGGSGGS | |
M-B3-ELP | Myristoyl | GLSLSRGGSGGS | ||
M-B1 | Myristoyl | GAGASR | ||
M-B2 | Myristoyl | GAGAGAYR | N/A | |
Controls | M-B3 | Myristoyl | GLSLSR | |
ELP | N/A | N/A | (GVGVP)40GY | |
M-ELP | Myristoyl | N/A | (GVGVP)40GY |
Amino acid abbreviations: Gly, G; Ala, A; Ser, S; Arg, R; Tyr, Y; Leu, L, Val, V and Pro, P. De novo designed recognition sequences contain a β-sheet forming domain (bold), trypsin cleavage site (Arg, underlined), and a flexible linker (italics).